Blackstone Life Sciences
Signal active
Investment Firm
Overview
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
Highlights
Founded
2005
Industry
Employees
0
Investment
15
Lead Investment
9
Exits
13
Stages
Early Stage Venture, Late Stage Venture
Investor Type
Private Equity Firm
Location
United States, North America
Contact Information
Social
Profile Resume
Blackstone Life Sciences, established in 2005 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across Biotechnology, Medical, Health Care, Pharmaceutical, Therapeutics, Genetics, Biopharma, Precision Medicine, Information Technology, Financial Services. The organization boasts a portfolio of 15 investments, with an average round size of $299.3M and 13 successful exits. Their recent investments include Uniquity Bio, Moderna, Amicus Therapeutics, Anthos Therapeutics, Novartis. The highest investment round they participated in was $135.5B. Among their most notable exits are Uniquity Bio and Moderna. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Blackstone Life Sciences has made 15 investments. Their most recent investment was on May 15, 2024, when Uniquity Bio raised $300.0M.
Blackstone Life Sciences has made 1 diversity investments. Their most recent diversity investment was on Oct 06, 2020, when Talaris Therapeutics raised $115.0M.
investments
15
Diversity investments
1
Lead investments
9
Number of exits
13
Investments
15
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jun 26, 2023 | Sutro Biopharma | Information Technology | 140.0M |
| Oct 02, 2023 | Amicus Therapeutics | Biotechnology | 30.0M |
| Mar 27, 2024 | Moderna | Biotechnology | 750.0M |
| May 15, 2024 | Uniquity Bio | Biotechnology | 300.0M |
Amicus TherapeuticsExits
13
Funding Timeline
Funding rounds
15
Investors
0
Funds
0
Funding Rounds
15
Blackstone Life Sciences has raised 15 rounds. Their latest funding was raised on May 15, 2024 from a Series A - Uniquity Bio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jun 26, 2023 | Post-IPO Debt - Sutro Biopharma | - | 140.0M | - |
| Oct 02, 2023 | Post-IPO Equity - Amicus Therapeutics | - | 30.0M | - |
| Mar 27, 2024 | Post-IPO Equity - Moderna | - | 750.0M | - |
| May 15, 2024 | Series A - Uniquity Bio | - | 300.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
N/A
Recent Activity
There is no recent news or activity for this profile.